Needham Reiterates Buy on Cormedix, Maintains $13 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Serge Belanger has reiterated a Buy rating on Cormedix (NASDAQ:CRMD) and maintained a $13 price target.

June 21, 2023 | 3:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger reiterated a Buy rating on Cormedix (NASDAQ:CRMD) and maintained a $13 price target.
The reiteration of a Buy rating and maintenance of a $13 price target by Needham analyst Serge Belanger indicates a positive outlook for Cormedix's stock. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100